Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New balloon aims to clear calcified leg arteries safely

NCT ID NCT07397390

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a special balloon designed to open up hardened leg arteries in people with peripheral artery disease. About 58 participants with moderate to severe calcium buildup will receive the balloon treatment. Researchers will check if the balloon successfully widens the artery and improves blood flow, and will follow patients for 6 months to see if further procedures are needed.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
DKutting LL scoring balloon (a medical device used to widen narrowed arteries)
What this could lead to
If successful, this balloon could offer a safer, more effective way to prepare hardened leg arteries for treatment, potentially reducing complications and repeat procedures.
What could go wrong
This is a small, early-stage study with only 58 participants and no comparison group. The balloon may not work better than standard treatments, and risks like artery damage or blockage remain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 58 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

lower limb ischemia caused by calcified lesion in femoral-popliteal and infra-popliteal artery

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years and ≤ 85 years. * Clinical diagnosis of lower extremity atherosclerotic arterial disease, with a Rutherford Classification of Category 2-5. * The patient has provided written informed consent. * Life expectancy \> 1 year. * Confirmed by clinical and CTA examination: de novo or restenotic lesions after PTA in the femoropopliteal or infrapopliteal arteries, with no stent implantation within 2 cm of the target lesion. Stenosis ≥70% or chronic total occlusion (CTO). * Lesion confirmed by CTA and color Doppler to have moderate to severe calcification (PACSS Grade 3-4). Lesion can be single or tandem, with a total length ≤150 mm. Reference vessel diameter near the target lesion ≥2 mm. * Allowable location of the target lesion: ≥1 cm distal to the common femoral artery bifurcation, and up to 10 cm above the ankle. * If the lesion is below-the-knee (BTK), the inflow vessels must have no non-target lesions, or any non-target lesions must be successfully treated with the current device without vascular complications. * No serious vascular complications such as flow-limiting dissection occur after pre-dilation of the target lesion. * Presence of at least one reconstructible infrapopliteal runoff vessel patent to the ankle. Exclusion Criteria: * Allergy to contrast media. * Coagulopathy; severe hepatic insufficiency (ALT or AST \> 3 times the upper limit of normal). * Cardiac insufficiency (New York Heart Association Class III-IV). * Life expectancy \< 1 year. * Acute cardiovascular events (e.g., acute myocardial infarction, stroke) within the past 3 months; active gastrointestinal bleeding affecting the use of anticoagulant/antiplatelet therapy. * Previous stent implantation or bypass surgery in the target vessel. * Acute/subacute limb ischemia or thrombotic lesions. * Contraindications to anticoagulation or antiplatelet therapy. * Failure to cross the lesion with a guidewire during the procedure; anticipation that the IVUS catheter or DKutting balloon will be unable to cross the lesion after pre-dilation. * Intraoperative occurrence of severe complications requiring conversion to other treatment methods (e.g., bypass surgery). * Pregnant or lactating women. * Active infection at the intended treatment site; foot wounds reaching WIfI Stage 3, or ankle/foot ulcers primarily of non-ischemic etiology. * Patient withdrawal of informed consent. * Planned amputation. * Planned use of adjunctive therapy devices (e.g., atherectomy, laser). * Participation in another interventional drug/device clinical study for lower limb arteries where the primary endpoint has not been reached, or planned participation in such a study. * Patient is bedridden or unable to walk. * Presence of an aneurysm in the ipsilateral limb vasculature.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Angioplasty are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The First Affiliated Hospital of Dalian Medical University

    Dalian, Liaoning, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.